Docetaxel inhibits progression of human hepatoma cell line in vitro and is effective in advanced hepatocellular carcinoma

Hepatology Research

Volumn 40, Issue 3, 2010, Pages 304-310

  Yata, Yutaka ^a,b   Xue, Feng ^a,c   Takahara, Terumi ^a   Kudo, Hiroshi ^a   Hirano, Katsuharu ^a   Yasumura, Satoshi ^a   Minemura, Masami ^a   Scanga, Andrew E ^d   Sugiyama, Toshiro ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Docetaxel; Hepatocellular carcinoma; Human hepatoma cell line; In vitro; Personalized medicine

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; SORAFENIB;

ADULT; ADVANCED CANCER; ARTICLE; ARTIFICIAL EMBOLISM; ASCITES; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOMATOUS PERITONITIS; CASE REPORT; CHEMOSENSITIVITY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION;

EID: 77954351999     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00598.x     Document Type: Article

References (19)

1. Donnellan P, Armstrong J, Rowan S. New chemotherapy combinations with docetaxel in the treatment of patients with non-small cell lung cancer. Semin Oncol 1998, 25:20-3.
2. Coleman RE, Howell A, Eggleton SP, Maling SJ, Miles DW. Phase II study of docetaxel in patients with liver metastases from breast cancer. UK study group. Ann Oncol 2000, 11:541-6.
3. Papakostas P, Tsavdaridis D, Kosmidis P. Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group phase II study. Gastric Cancer 2006, 9:26-31.
4. Romano O, Truant S, Sergent-Baudson G, Comet B, Pruvot FR, Hebbar M. Docetaxel therapy for advanced hepatocellular carcinoma developed in healthy liver: report of three cases. J Chemother 2008, 20:518-20.
5. Ishikawa T, Ichida T, Yokoyama J, Matsuda Y, Watanabe T, Asakura H. Complete disappearance of pulmonary metastases in a case of hepatocellular carcinoma treated with docetaxel-based systemic chemotherapy. J Gastroenterol Hepatol 2004, 19:1423-6.
6. Hebbar M, Ernst O, Cattan S. Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma. Oncology 2006, 70:154-8.
7. Xue F, Takahara T, Yata Y. Blockade of Rho/Rho-associated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-dependent manner. Hepatol Res 2008, 38:810-17.
8. Llovet JP, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-90.
9. Yau T, Chan P, Epstein R, Poon RT. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 2009, 29:10-17.
10. Bissery MC, Guénard D, Guéritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991, 51:4845-52.
11. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 1995, 6:363-8.
12. Vanhoefer U, Cao S, Harstrick A, Seeber S, Rustum YM. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Ann Oncol 1997, 8:1221-8.
13. Papakostas P, Kouroussis C, Androulakis N. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study. Eur J Cancer 2001, 37:1833-8.
14. Geng CX, Zeng ZC, Wang JY, Xuan SY, Lin CM. Docetaxel shows radiosensitization in human hepatocellular carcinoma cells. World J Gastroenterol 2005, 11:2990-3.
15. Feliu J, Firvida JL, Castro J. Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study. Cancer Chemother Pharmacol 2009, 63:403-9.
16. Bissery MC, Vrignaud P, Lavelle F. Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination. Semin Oncol 1995, 22:3-16.
17. Ajani JA. Docetaxel in combination for advanced gastric cancer. Gastric cancer 2002, 5:31-4.
18. Benhadji KA, Serova M, Ghoul A. Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. Br J Cancer 2008, 99:1808-15.
19. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48:1312-27.